Nanomaterials in tumor immunotherapy: new strategies and challenges

X Zhu, S Li - Molecular Cancer, 2023 - Springer
Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune
responses of the body. It has become another important modality of anti-tumor therapy with …

[HTML][HTML] Simulation-based approaches for drug delivery systems: Navigating advancements, opportunities, and challenges

I Salahshoori, M Golriz, MAL Nobre, S Mahdavi… - Journal of Molecular …, 2024 - Elsevier
Efficient drug delivery systems (DDSs) play a pivotal role in ensuring pharmaceuticals'
targeted and effective administration. However, the intricate interplay between drug …

A self-charging salt water battery for antitumor therapy

J Huang, P Yu, M Liao, X Dong, J Xu, J Ming, D Bin… - Science …, 2023 - science.org
Implantable devices on the tumor tissue as a local treatment are able to work in situ, which
minimizes systemic toxicities and adverse effects. Here, we demonstrated an implantable …

Nanomaterials: breaking through the bottleneck of tumor immunotherapy

Y Kang, S Li - International Journal of Biological Macromolecules, 2023 - Elsevier
Immunotherapy exerts its excellent anti-tumor effects by stimulating and enhancing the
immune response of the body, and has become another important class of anti-tumor …

Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells

N Desai, U Hasan, K Jeyashree, R Mani, M Chauhan… - Acta Biomaterialia, 2023 - Elsevier
Immunotherapy involves the therapeutic alteration of the patient's immune system to identify,
target, and eliminate cancer cells. Dendritic cells, macrophages, myeloid-derived …

Is the new angel better than the old devil? Challenges and opportunities in CD47-SIRPα-based cancer therapy

OT Olaoba, KS Ayinde, OM Lateef… - Critical Reviews in …, 2023 - Elsevier
The efficacy of immunotherapies is limited due to the impenetrable nature of the tumor
microenvironment (TME). The TME of many tumors is immune-privileged, thus allowing them …

[HTML][HTML] Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma

L Fang, W Tian, C Zhang, X Wang, W Li… - Pharmacological …, 2023 - Elsevier
Chimeric antigen receptor T-cell (CAR-T) is particularly prominent in hematological but not
in solid tumors, mainly based on the complex tumor immune microenvironment. Oncolytic …

Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?

Y Peng, H Yan, W Mei, P Zhang, C Zeng - Current Treatment Options in …, 2023 - Springer
Opinion statement Combining immunotherapy and radiotherapy as a treatment strategy for
cervical cancer has attracted increasing attention. The primary objective of this review is to …

Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis

KA Iyer, J Ivanov, R Tenchov, K Ralhan… - Journal of Medicinal …, 2024 - ACS Publications
In the ever-evolving landscape of cancer research, immuno-oncology stands as a beacon of
hope, offering novel avenues for treatment. This study capitalizes on the vast repository of …

Highlighting novel targets in immunotherapy for liver cancer

SM Ruff, AH Shannon, JD Beane… - Expert review of …, 2022 - Taylor & Francis
Introduction Alterations to the hepatic immune microenvironment can play a key role in the
development and progression of cancer. This is especially true in the liver due to its …